Med-Chemist

Med-Chemist : "Quintessential Medicinal Chemistry"

Showing posts with label Recurrent Low-Grade Intermediate-Risk. Show all posts
Showing posts with label Recurrent Low-Grade Intermediate-Risk. Show all posts
Thursday, October 23, 2025

FDA Approves Zusduri (mitomycin) for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

›
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial ...
›
Home
View web version

Contributors

  • Dr. Umesh..
  • https://www.med-chemist.com
Powered by Blogger.